This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Astrazeneca Ab. Active years: 2022-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2026
Title: David Clark - Innovator in Cardiovascular Treatments
Introduction
David Clark is a prominent inventor based in Cambridge, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for cardiovascular diseases. His innovative work has the potential to impact many lives.
Latest Patents
David Clark holds a patent for PCSK9 inhibitors and methods of use thereof. This invention relates to novel heteroaryl compounds of Formula (I) and pharmaceutical preparations thereof. The invention further encompasses methods of treating or preventing cardiovascular diseases, as well as methods for treating sepsis or septic shock, using the novel heterocyclic compounds disclosed in the patent. He has 1 patent to his name.
Career Highlights
David Clark is associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to focus on innovative solutions for complex health issues, particularly in the cardiovascular domain.
Collaborations
David has collaborated with notable colleagues, including Michael H Serrano-Wu and Mark Chambers. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic approaches.
Conclusion
David Clark's contributions to the field of pharmaceuticals, particularly through his patent on PCSK9 inhibitors, highlight his role as an innovator in cardiovascular treatments. His work continues to pave the way for advancements in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile